Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Christopher Kapolas, PharmD, Jane Kosirog-Glowacki, PharmD, Kathryn L Barney, NP, Linda Advincula, NP, Leonard M. Klein, MD, Jacob D. Bitran, MD, Shams Bufalino, Tulio E Rodriguez, MD

Blood (2018) 132 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2018-99-120189

Published: 2018

Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2018) 132 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2018-99-114409

Published: 2018

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 4152.

https://doi.org/10.1182/blood.V126.23.4152.4152

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Clarence Eng, MPH, Jing He, Jing Hu, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 1545.

https://doi.org/10.1182/blood.V126.23.1545.1545

Published: 2015

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Jeff P. Sharman, MD, Charles M. Farber, MD PhD, Daruka Mahadevan, MD PhD, Marshall T. Schreeder, MD, Heather D. Brooks, MD, Kathryn S. Kolibaba, MD, Suzanne R. Fanning, DO, Leonard M. Klein, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Daniel R. Greenwald, MD

Blood (2014) 124 (21): 4679.

https://doi.org/10.1182/blood.V124.21.4679.4679

Published: 2014

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Steve Abella, MD, Meihua Wu, PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 4419.

https://doi.org/10.1182/blood.V124.21.4419.4419

Published: 2014

Journal Articles

Single Donor Versus Acrodose Platelets in Oncology Patients: A Single Institutional Experience

Neil Dalal, DO, Naveed Cheema, D.O., Leonard M. Klein, MD

Blood (2014) 124 (21): 4298.

https://doi.org/10.1182/blood.V124.21.4298.4298

Published: 2014

Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 2979.

https://doi.org/10.1182/blood.V120.21.2979.2979

Published: 2012

NARROW

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

Single Donor Versus Acrodose Platelets in Oncology Patients: A Single Institutional Experience

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only